Retrospective Epidemiological Study on Botulism in Intensive Care Units in France

Proportion of patients alive at ICU discharge

Mean age of recruited patients

Mean weight of recruited patients

Mean Height of recruited patients

History of neurological disorder with motor impairment before the poisoning, measured by the Modified Rankin Scale (0 to 6, 0 being no symptoms and 6 being deceased).

History of heart failure before the poisoning, measured by the NYHA (New York health Association) dyspnoea score (1 to 4, 1 being no symptoms and no limitation in daily physical activity, 4 being severe symptoms even at rest).

Chronic respiratory failure defined by the use of chronic oxygen therapy AND/OR daily non invasive ventilation.

History of chronic kidney disease before the poisoning, defined as a glomerular filtration rate < 60 mL/min/1.73m for more than 3 months OR chronic dialysis.

Presence or absence of Cirrhosis, as measured by the CHILD-PUGH score (class A, B or C, A predicting a one year survival probability of 100%, C predicting a one year survival probability of 45%).

Suspected origin of the toxin: food poisoning, dermal wound, intravenous drug use, intestinal colonisation by Clostridium sp. or unknown.

Whether the poisoning is isolated or one of multiple cases originating from the same source.

Botulinum toxin type if identified (A,B,C,D,E,F,G or H type toxin).

Simplified acute physiology score 2 (SAPS 2) at admission in the ICU: from 0 to 163, with 0 predicting a mortality risk of 0% and 163 of 100%.

Whether the patient required or not mechanical ventilation during his ICU stay

Whether the patient required or not invasive mechanical ventilation during his ICU stay

Whether the patient required or not non invasive mechanical ventilation during his ICU stay

Whether the patient required a tracheotomy during his ICU stay

Whether the patient required or not enteral or parenteral nutritional support during his ICU stay

Number of days the patient required vasopressor support during his ICU stay

Whether the patient developped an acute kidney injury during his ICU stay: measured by maximum serum creatinine during ICU stay in µmol/L.

Whether the patient developped an acute severe liver failure during his ICU stay, defined as a prothrombin time less than 50% due to liver failure.

Whether botulinum antitoxin was administered.

Whether guanidine was administered as a treatment for the botulinum poisoning.

Number of hospitalisation days in the ICU.

Whether the patient acquired a healthcare related infection during his stay in the ICU.

Whether the patient had any mechanical ventilation related complications during his stay in the ICU.

Whether the patient acquired bedsores during his ICU stay.

Whether the patient acquired thrombo-embolic complications (deep vein thrombosis or pulmonary embolism) during his ICU stay.

Modified Rankin scale at ICU discharge, from 0 to 6, with 0 being asymptomatic and 6 being death.

Modified Rankin scale at hospital discharge, from 0 to 6, with 0 being asymptomatic and 6 being death.

Last known modified Rankin scale, from 0 to 6, with 0 being asymptomatic and 6 being death.

Proportion of patients alive at hospital discharge